Skip to main content

Evotec SE

EVO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001412558

No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.

Other share classesEVOTF

Holders of 5% or more of EVO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evotec SE, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of EVO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Excalibur LuxCo SARL13D/A9.99%17.7M shares–Oct 29, 20251 filingOct 29, 2025SEC
MAK Capital Fund LP13D7.00%12.5M shares+1.70 ppfrom 5.30%Jan 16, 20262 filingsMar 30, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Evotec SE, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on EVO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 30, 20268:29 PM ETMAK Capital Fund LPand 2 others13D7.00%12.5M shares+1.70 ppfrom 5.30%Mar 30, 2026SEC
Feb 17, 20266:54 PM ETNovo Holdings A/S13G/A0.00%0 shares−5.30 ppfrom 5.30%Below 5%Dec 31, 2025SEC
Jan 16, 20264:06 PM ETMAK Capital Fund LPand 2 others13G5.30%9.39M sharesNewJan 9, 2026SEC
Nov 14, 20256:30 PM ETNovo Holdings A/S13G/A5.30%9.41M shares–Sep 30, 2025SEC
Oct 29, 20255:24 PM ETExcalibur LuxCo SARLand 4 others13D/A9.99%17.7M shares–Oct 27, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Evotec SE shares.

No Form 144 notices for Evotec SE are on file.